SCHEMBL4497497

SCHEMBL4497497

CCOC(=O)c1cnc(Cl)c([N+](=O)[O-])c1N

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
MAPT P10636 6/20 0.46
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
KMT2A Q03164 3/20 0.44
HSP90AA1 P07900 1/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 5/20 0.43
MEN1 O00255 2/20 0.43
HPGD P15428 2/20 0.42
GLA P06280 1/20 0.42
PKM P14618 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CSNK1D P48730 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27314724 0.86 ALDH1A1 (0.49) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL30846439 0.86 ALDH1A1 (0.49) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL574989 0.86 ALDH1A1 (0.49) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL31733261 0.86 ALDH1A1 (0.49) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL31523457 0.85 MAPT (0.39) ALDH1A1MAPTKMT2APOLBKDM4E
SCHEMBL14031475 0.84 ALDH1A1 (0.47) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL4766494 0.82 ALDH1A1 (0.46) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL14468617 0.82 ALDH1A1 (0.46) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL14468616 0.82 ALDH1A1 (0.46) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL24455485 0.81 ALDH1A1 (0.45) ALDH1A1MAPTNPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025236100-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2025-11-20 WO disclosed
US-7635695-B2 Antiinflammation agents AMGEN INC. (US) 2009-12-22 US disclosed
US-7635695-B2 Antiinflammation agents AMGEN INC. (US) 2009-12-22 US disclosed
US-20070155777-A1 Antiinflammation agents AMGEN, INC. 2007-07-05 US disclosed
US-20070155777-A1 Antiinflammation agents AMGEN, INC. 2007-07-05 US disclosed
US-7199119-B2 Antiinflammation agents AMGEN INC. (US) 2007-04-03 US disclosed
US-7199119-B2 Antiinflammation agents AMGEN INC. (US) 2007-04-03 US disclosed
US-7199119-B2 Antiinflammation agents AMGEN INC. (US) 2007-04-03 US disclosed
EP-1556053-A4 ANTIINFLAMMATION AGENTS AMGEN INC (US) 2006-04-19 EP disclosed
EP-1556053-A1 ANTIINFLAMMATION AGENTS Amgen Inc. (US) 2005-07-27 EP disclosed
WO-2004041285-A1 ANTIINFLAMMATION AGENTS AMGEN INC. (US) 2004-05-21 WO disclosed
US-20040097485-A1 Antiinflammation agents TULARIK INC. 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155777-A1 Antiinflammation agents TNF, NFATC1, NFKBIA ALDH1A1 3037/4885MAPT 3631/4885NPC1 1825/4885
US-20040097485-A1 Antiinflammation agents TNF, NFATC1, NFKBIA ALDH1A1 3037/4885MAPT 3631/4885NPC1 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.